Syndax Pharmaceuticals, Inc. SNDX
Nov 4, 2026, 11:40 AM EST
- YTD
- -49.70%
- 1 year
- -31.15%
- Market cap
- 948.90M
- Revenue (ttm)
- 252.25M
- Profit margin
- -87.52%
- EPS (ttm)
- -2.37
- Shares out
- 89.30M
- Forward P/E
- -19.70
- YTD return
- -49.70%
- 1-year return
- -31.15%
- Volume
- 5.83M
- Avg volume
- 2.03M
- Open
- 14.55
- Previous close
- 14.29
- Day's range
- 10.50 – 14.69
- 52-week range
- 10.50 – 25.59
- Beta
- 0.45
- Analysts
- Strong Buy
- Price target
- 37.27 (+252.7%)
- Earnings date
- Feb 25, 2027
5Y -5.34 (-30.34%)
Key statistics
- Enterprise value
- 1.20B
- PEG ratio
- 0.00
- Price / sales
- 5.06
- Price / book
- 19.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 91.80%
- Free cash flow
- -150.08M
- Total cash
- 554.27M
- Total debt
- 589.38M
- Return on equity
- -255.93%
- Short % of float
- 20.51%
- 50-day average
- 17.05
- 200-day average
- 20.20
Analyst view
Consensus: strong buy
- Target (low)
- 23.00
- Target (mean)
- 37.27
- Target (high)
- 57.00
- Strong buy2
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.48378.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.52 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | -0.50408 | -0.55 | -0.05 | -9.11% |
| Aug 4, 2026 | Jun 30, 2026 | -0.44767 | -0.55 | -0.10 | -22.86% |
| Apr 30, 2026 | Mar 31, 2026 | -0.59 | -0.48 | +0.11 | +18.64% |
| Feb 26, 2026 | Dec 31, 2025 | -0.58404 | -0.78 | -0.20 | -33.55% |
| Nov 3, 2025 | Sep 30, 2025 | -0.74 | -0.70 | +0.04 | +5.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 13, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2026 | UBS | main | Buy | Buy |
| Aug 11, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 5, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- syndax.com
News
Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key 
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026 
Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026 
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX 
Apple To $350? Here Are 10 Top Analyst Forecasts For Tuesday 
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $36 
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2026 Earnings Call Transcript 
What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call 
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue Estimates 
Syndax Pharmaceuticals Q3 EPS $(0.55) Misses $(0.49) Estimate, Sales $83.298M Beat $81.850M Estimate
Your note
Sign in to keep a note on SNDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOTWOOD NICHOLAS A.J. | Officer | Sale | Jun 11, 2026 | 60,885 |
| GALLAGHER NEIL | Officer | Sale | Feb 9, 2025 | 85,095 |
| GOLDAN KEITH ALAN | Chief Financial Officer | Sale | May 31, 2026 | 139,252 |
| HUBER MARTIN H JR | Director | Stock Award(Grant) | Feb 3, 2026 | 103,000 |
| JARRETT A JENNIFER | Director | Stock Award(Grant) | Feb 3, 2026 | 114,000 |
| KATKIN KEITH A | Director | Stock Award(Grant) | Feb 3, 2026 | 124,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.18% | 9,020,006 | 128.90M | Jun 29, 2026 |
| Kynam Capital Management, LP | 9.09% | 8,050,959 | 115.05M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 6.61% | 5,861,265 | 83.76M | Jun 29, 2026 |
| State Street Corporation | 6.39% | 5,658,424 | 80.86M | Jun 29, 2026 |
| Bank of America Corporation | 4.57% | 4,045,094 | 57.80M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.43% | 3,927,892 | 56.13M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.19% | 2,823,912 | 40.35M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.87% | 2,547,266 | 36.40M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.59% | 2,296,035 | 32.81M | Sep 29, 2026 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 1.37% | 1,211,108 | 17.31M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.14% | 1,013,559 | 14.48M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.10% | 973,449 | 13.91M | Aug 30, 2026 |